Dermapharm Holding SE Reports Strong Q3 2024 Results

Dermapharm Holding SE, a rapidly expanding manufacturer of branded pharmaceuticals and healthcare products, announced robust results for Q3 2024. The company's consolidated revenue rose by 2.7% to EUR 890.1 million, driven by growth in the high-margin "Branded pharmaceuticals" segment. Despite challenges, this growth surpassed the downturn in the "Other healthcare products" segment.

The unadjusted consolidated EBITDA jumped 12.3% to EUR 234.1 million, with a margin improvement of 2.3 percentage points to 26.3%. The adjusted EBITDA reached EUR 240.3 million, marking a 27.0% margin.

Q3 2024 alone saw a remarkable 9.5% increase in revenue compared to the previous year, supported by progress in the branded pharmaceuticals sector and Arkopharma's performance. Dermapharm's Board maintains its full-year forecast, anticipating revenues between EUR 1,170 million and EUR 1,210 million, with an adjusted EBITDA of EUR 305–315 million.